With specialized care, patients with myasthenia gravis can have very good 
outcomes. The mainstays of treatment are acetylcholinesterase inhibitors, and 
immunosuppressive and immunomodulatory therapies. There is good evidence 
thymectomy is beneficial in thymomatous and nonthymomatous disease. Nearly all 
of the drugs used for MG are considered "off-label." The 2 exceptions are 
acetylcholinesterase inhibitors and complement inhibition with eculizumab, which 
was recently approved by the US Food and Drug Administration for myasthenia 
gravis. This article reviews the evidence base and provides a framework for the 
treatment of myasthenia gravis, highlighting recent additions to the literature.